Myelofibrosis – Life with Disease

Go back

Myelofibrosis is a rare blood cancer that causes scarring in the bone marrow, making it difficult for the body to produce healthy blood cells. Understanding how this condition may progress and affect daily life is crucial for patients and their families navigating this challenging diagnosis.

Understanding the Long-Term Outlook for Myelofibrosis

When someone receives a diagnosis of myelofibrosis, one of the first questions that naturally comes to mind concerns what the future might hold. The outlook for myelofibrosis varies greatly from person to person, depending on several important factors that doctors carefully evaluate[2].

Medical professionals use specific scoring systems to help predict how the disease might progress. The International Prognostic Scoring System (IPSS) and the Dynamic International Prognostic Scoring System (DIPSS) help doctors classify patients into risk groups—low, intermediate-1, intermediate-2, or high risk. These classifications are based on factors such as age (whether over 65), white blood cell levels, hemoglobin count, the presence of immature blood cells called blasts, and symptoms like weight loss or night sweats[14].

People with low-risk myelofibrosis can sometimes keep their condition under control for several years. The disease in these cases may progress slowly, allowing individuals to maintain a relatively normal quality of life with careful monitoring. On the other hand, high-risk myelofibrosis can be more difficult to manage and may progress more quickly[14].

Myelofibrosis is described as a lifelong condition that often progresses slowly. However, it can sometimes worsen rapidly and, in some cases, may transform into an aggressive type of acute leukemia. This is why healthcare providers manage care very closely once a diagnosis is made[2].

⚠️ Important
The predicted outlook of myelofibrosis depends on many individual factors. It is best to discuss your specific prognosis with your own specialist, who has access to all your test results and can see how they have changed over time. No two patients follow exactly the same path with this disease.

How Myelofibrosis Progresses Without Treatment

Understanding how myelofibrosis develops naturally helps patients and families know what changes to watch for and when medical intervention might become necessary. In its earliest stages, myelofibrosis may be completely silent. Many people experience no symptoms at all initially, even though changes are already occurring in their bone marrow[5].

The disease typically begins when abnormal blood stem cells in the bone marrow start multiplying. These abnormal cells produce copies of themselves that build up and crowd out healthy blood cells. They also release substances that damage the bone marrow tissue, leading to scarring inside the bones. This scarring process, called fibrosis, is where the disease gets its name[2].

As the scarring progresses, the bone marrow becomes less and less capable of performing its essential job—making healthy red blood cells, white blood cells, and platelets. When the bone marrow can no longer produce enough blood cells, other organs try to compensate. The spleen, which normally filters blood, may start attempting to produce blood cells itself. This causes the spleen to enlarge, a condition called splenomegaly. The liver may also enlarge as it tries to help with blood cell production[3].

Without treatment, people typically begin experiencing symptoms as their blood cell counts become increasingly abnormal. Anemia develops as red blood cell production drops, leading to fatigue, weakness, and shortness of breath. Low platelet counts can result in easy bruising and bleeding. An enlarged spleen may cause abdominal fullness, discomfort, or pain under the left ribs. Weight loss, night sweats, fever, bone pain, and itching may also develop as the disease progresses[1].

The natural course of untreated myelofibrosis can lead to serious complications. Blood cell production may move outside the bone marrow to other organs, causing further problems. The disease may also evolve, with some patients developing acute myeloid leukemia, which is a more aggressive form of blood cancer[2].

Potential Complications That May Arise

Myelofibrosis can lead to several serious complications as it advances, affecting multiple body systems beyond just the bone marrow. Understanding these potential complications helps patients recognize warning signs and seek timely medical attention.

One of the most concerning complications is the progression to acute myeloid leukemia (AML). This represents a transformation of myelofibrosis into its most aggressive form. AML is a type of leukemia where immature blood cells rapidly multiply and crowd out normal cells. This complication requires urgent medical intervention[2].

Decreased blood cell production becomes increasingly problematic as scarring in the bone marrow worsens. Severe anemia can develop, making people feel exhausted and breathless even with minimal activity. Low platelet counts increase bleeding risks, which can become dangerous if injuries occur or if bleeding happens internally[2].

When blood cells can’t form properly in the bone marrow, the body may start producing them in unusual places. This abnormal blood cell production can occur in the spleen, liver, or other organs. The growth of these out-of-place blood cells can cause tumors and put pressure on nearby structures. This is particularly dangerous when it affects the portal vein, which carries blood from the spleen to the liver. The pressure can become so high that it causes serious bleeding[2].

The enlarged spleen itself can become a source of complications. As it grows, it can press against the stomach, causing people to feel full after eating only small amounts. The spleen may also become painful or tender. In rare cases, it can rupture, which is a medical emergency[3].

An enlarged liver can also cause problems, leading to abdominal swelling and discomfort. In advanced cases, liver function may become compromised, affecting the body’s ability to process nutrients and medications[7].

Infections become a greater risk as the disease progresses because the bone marrow cannot produce enough functioning white blood cells to fight off bacteria and viruses. People with myelofibrosis may find themselves getting infections more easily and having difficulty recovering from them[2].

Blood clots represent another serious complication. Despite having low platelet counts, some people with myelofibrosis are at increased risk for developing blood clots that can lead to heart attacks or strokes. This may seem contradictory, but it reflects the complex nature of how blood cells malfunction in this disease[2].

The Impact of Myelofibrosis on Everyday Activities

Living with myelofibrosis affects far more than just physical health—it touches nearly every aspect of daily life, from work and hobbies to relationships and emotional well-being. Understanding these impacts can help patients and families prepare and adapt.

Fatigue is often the most challenging symptom that affects daily routines. This isn’t ordinary tiredness that improves with rest—it’s a profound exhaustion caused by anemia that can make even simple tasks feel overwhelming. Getting dressed in the morning, preparing meals, or walking short distances may require considerable effort. Many people with myelofibrosis find they need to adjust their schedules around their energy levels, planning important activities for times when they feel strongest[15].

Work life often requires significant adjustments. Some people decide to reduce their work hours or take early retirement because managing a full workday becomes too difficult. Others negotiate arrangements with employers to work from home or take frequent breaks during the day. The unpredictability of symptoms can make it hard to commit to fixed schedules or demanding projects[15].

Physical activities and hobbies may need modification. Exercise, while beneficial, must be approached carefully and adapted to individual capabilities and energy levels. Activities that were once enjoyable might become too strenuous. Walking, gentle stretching, or yoga may replace more vigorous forms of exercise. It’s important to work with healthcare teams to determine appropriate activity levels[19].

Household chores can pile up quickly when fatigue strikes. Many people find they need to ask family members or friends for help with tasks like cleaning, grocery shopping, or yard work. Some hire professional help for these activities. Breaking tasks into smaller, manageable pieces and resting between them can make daily chores more achievable[16].

Eating and nutrition can become complicated when an enlarged spleen presses against the stomach, causing early satiety—feeling full after eating only small amounts. This makes it difficult to maintain proper nutrition and can lead to unintended weight loss. People often need to eat smaller, more frequent meals throughout the day rather than three traditional large meals[17].

Sleep may be disrupted by night sweats, which can be so severe that people wake up drenched and need to change their clothing and bedding. This interrupts restorative sleep and contributes to daytime fatigue. Creating a comfortable sleep environment and having extra bedding readily available can help manage this challenge[19].

Pain—whether from bones, joints, or an enlarged spleen—can interfere with concentration, mood, and the ability to participate in social activities. Managing pain effectively requires working closely with healthcare providers to find appropriate pain relief strategies that don’t interfere with other treatments[16].

Social and emotional impacts can be profound. The invisible nature of many symptoms means that others may not understand why someone looks fine but feels terrible. This can strain relationships with friends, family, and colleagues who don’t grasp the reality of living with chronic illness. Some people experience feelings of isolation, anxiety about the future, or depression. These emotional challenges are normal responses to a serious diagnosis and deserve attention and support[17].

Medical appointments become a regular part of life, requiring time for checkups, blood tests, and consultations. Keeping track of these appointments, remembering to attend them, and managing the information shared during visits can feel like a job in itself. Many people find it helpful to use calendars, planners, or mobile apps to stay organized[15].

⚠️ Important
Adjusting to life with myelofibrosis takes time and patience. Setting small, realistic goals, focusing on what you can control, and finding joy in everyday moments can help you stay positive. Whether it’s connecting with loved ones, engaging in hobbies when you feel up to it, or practicing self-care, these small steps can make a real difference in your overall well-being.

Supporting Family Members Through Clinical Trial Participation

When someone with myelofibrosis is considering or participating in clinical trials, family members can play a vital supportive role. Understanding how to help effectively makes the experience less overwhelming for everyone involved.

Family members should first educate themselves about what clinical trials are and why they might be valuable for myelofibrosis patients. Clinical trials test new treatments or combinations of treatments that may not yet be widely available. For some patients, especially those with intermediate-2 or high-risk disease, clinical trials may offer access to promising new therapies that could help manage symptoms or slow disease progression[10].

Relatives can help by assisting with research. Looking up information about available clinical trials, understanding eligibility requirements, and identifying trials that might be appropriate can be time-consuming work. Family members with internet access and research skills can compile this information and help organize it in an easy-to-understand format. Many organizations and medical centers maintain databases of ongoing clinical trials for myelofibrosis[18].

Emotional support during the decision-making process is invaluable. Deciding whether to participate in a clinical trial involves weighing potential benefits against possible risks and unknowns. This can be stressful and confusing. Family members can help by listening without judgment, asking thoughtful questions, and attending medical appointments to help process the information being shared by healthcare providers.

Practical assistance becomes especially important once someone enrolls in a clinical trial. Trials often require frequent visits to medical centers, which may be far from home. Family members can help with transportation to and from appointments, especially if the patient feels unwell or receives treatments that make driving unsafe. They can also help manage the schedule of appointments, which may be more frequent than regular medical visits.

Keeping detailed records is often required in clinical trials. Family members can assist by maintaining organized files of medical records, tracking symptoms or side effects, and helping complete any questionnaires or diaries that the trial requires. This documentation is crucial for researchers but can feel burdensome for patients already dealing with fatigue and illness.

Providing physical care may become necessary if trial treatments cause side effects. Family members can help monitor for any concerning symptoms, ensure medications are taken as prescribed, prepare nutritious meals, and help with daily activities when fatigue or other symptoms become overwhelming.

It’s important for family members to also take care of themselves during this process. Supporting someone through a clinical trial can be emotionally and physically draining. Seeking support from other caregivers, joining support groups, or speaking with counselors can help family members maintain their own well-being while supporting their loved one[21].

Communication with the medical team is essential. Family members should feel empowered to ask questions about the trial, understand what to expect, and know when to report symptoms or concerns. Having a designated family member who attends appointments and communicates with healthcare providers can ensure consistency and prevent important information from being missed.

Finally, family members should respect their loved one’s autonomy and decisions. While offering support and information is helpful, the ultimate decision about participating in a clinical trial belongs to the patient. Supporting their choice, whatever it may be, is one of the most important things family members can do.

💊 Registered drugs used for this disease

List of officially registered medicines that are used in the treatment of this condition, based only on the provided sources:

  • Ruxolitinib (Jakafi) – A JAK1/JAK2 inhibitor approved by the FDA for treating intermediate or high-risk myelofibrosis, helping to reduce spleen size and relieve symptoms
  • Fedratinib (Inrebic) – A JAK inhibitor approved for the treatment of myelofibrosis
  • Pacritinib (Vonjo) – A JAK inhibitor approved for myelofibrosis treatment
  • Momelotinib (Ojjaara) – A JAK inhibitor approved for treating myelofibrosis
  • Hydroxyurea – Used to manage thrombocytosis and other symptoms in myelofibrosis patients
  • Erythropoietin – Supportive care medication used to help manage anemia in myelofibrosis
  • Oxymetholone – An androgen therapy used as supportive care for myelofibrosis
  • Danazol – An androgen therapy used as supportive care for myelofibrosis
  • Aredia (Pamidronate) – A bisphosphonate used in myelofibrosis treatment
  • Zometa (Zoledronic acid) – A bisphosphonate used in myelofibrosis treatment

Ongoing Clinical Trials on Myelofibrosis

  • A Study of Pacritinib for Reducing Bone Marrow Scarring in Patients with Myelofibrosis Who Have Low Platelet Counts

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Spain
  • Study of RVU120 treatment in patients with myelodysplastic syndrome, solid tumors, or acute myeloid leukemia who benefited from previous RVU120 therapy

    Recruiting

    2 1 1 1
    France Italy Poland Spain
  • Study on the Safety of Roginolisib and Ruxolitinib for Patients with Myelofibrosis Unresponsive to JAK Inhibitors

    Recruiting

    1 1 1 1
    Investigated diseases:
    Italy Spain
  • Study of TP-3654 and Momelotinib for Patients with Intermediate or High-risk Myelofibrosis

    Recruiting

    1 1 1
    Investigated diseases:
    Austria Belgium Bulgaria Czechia Denmark France +7
  • Study on Long-Term Safety of Pelabresib for Patients with Myelofibrosis or Essential Thrombocythemia

    Recruiting

    3 1 1
    Belgium Italy The Netherlands
  • Study on Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis and Suboptimal Response to Ruxolitinib

    Recruiting

    3 1 1
    Investigated diseases:
    Austria Belgium Croatia Czechia France Germany +7
  • Study on Long-Term Safety of Luspatercept for Patients with Myelodysplastic Syndrome, Beta-Thalassemia, or Myelofibrosis Who Previously Participated in Luspatercept Trials

    Recruiting

    3 1 1 1
    Investigated drugs:
    Bulgaria France Germany Greece Italy The Netherlands +2
  • Study on the Safety of Bomedemstat for Patients with Myeloproliferative Neoplasms Who Participated in a Previous Bomedemstat Study

    Recruiting

    3 1 1
    Investigated drugs:
    Italy
  • Study for Myelofibrosis Patients Using Ruxolitinib or Ruxolitinib with Other Cancer Treatments

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Poland
  • Study on the Effectiveness and Safety of Selinexor for Patients with Myelofibrosis and Moderate Thrombocytopenia Who Have Not Used JAK Inhibitors

    Recruiting

    2 1 1 1
    Investigated diseases:
    Belgium Bulgaria Czechia Denmark France Germany +7

References

https://www.mayoclinic.org/diseases-conditions/myelofibrosis/symptoms-causes/syc-20355057

https://my.clevelandclinic.org/health/diseases/15672-myelofibrosis

https://mpnresearchfoundation.org/primary-myelofibrosis-pmf/

https://www.mdanderson.org/cancerwise/7-things-to-know-about-myelofibrosis.h00-159776445.html

https://www.jakafi.com/myelofibrosis/what-is-myelofibrosis

https://www.leukaemia.org.au/blood-cancer/types-of-blood-cancer/myeloproliferative-neoplasms/primary-myelofibrosis/

https://www.aamds.org/diseases/related/myelofibrosis-mf

https://www.oncolink.org/cancers/blood-cancers/myelofibrosis/myelofibrosis-the-basics

https://www.mayoclinic.org/diseases-conditions/myelofibrosis/diagnosis-treatment/drc-20355062

https://www.mskcc.org/news/promising-new-treatment-for-myelofibrosis-blood-cancer-using-combination-targeted-therapy

https://my.clevelandclinic.org/health/diseases/15672-myelofibrosis

https://pmc.ncbi.nlm.nih.gov/articles/PMC4997889/

https://emedicine.medscape.com/article/197954-treatment

https://www.cancerresearchuk.org/about-cancer/myelofibrosis/tests-treatment

https://www.healthline.com/health/myelofibrosis/myelofibrosis-daily-life

https://www.webmd.com/cancer/lymphoma/myelofibrosis-self-care

https://www.mappingmf.com/charting-myelofibrosis/living-with-myelofibrosis/

https://www.cancercare.org/diagnosis/myelofibrosis

https://bloodcancer.org.uk/understanding-blood-cancer/myelofibrosis/looking-after-yourself-myelofibrosis/

https://massivebio.com/daily-life-with-myelofibrosis-tips-for-managing-symptoms/

https://www.voicesofmpn.com/myelofibrosis-support

https://www.mdanderson.org/cancerwise/7-things-to-know-about-myelofibrosis.h00-159776445.html

FAQ

Can myelofibrosis be cured?

Currently, allogeneic hematopoietic stem cell transplantation (bone marrow transplant) is the only potentially curative treatment option for myelofibrosis. However, this procedure carries significant risks and is typically considered for patients with high or intermediate-2 risk disease. Most treatments for myelofibrosis focus on managing symptoms and slowing disease progression rather than achieving a cure.

Why do I need treatment if I don’t have symptoms?

Many people with myelofibrosis don’t need treatment right away if they have no symptoms. This approach is called “watchful waiting.” Your healthcare provider will monitor your health closely through regular checkups and blood tests to watch for signs of disease progression. Treatment typically begins when symptoms develop or blood counts change significantly.

What causes the extreme fatigue I’m experiencing?

The fatigue in myelofibrosis is primarily caused by anemia—a low red blood cell count. Red blood cells carry oxygen throughout your body, so when there aren’t enough of them, your tissues don’t get adequate oxygen, leading to feelings of exhaustion, weakness, and shortness of breath even with minimal activity.

Is myelofibrosis hereditary?

In the majority of cases, myelofibrosis is not inherited genetically—you cannot pass the disease on to your children or inherit it from your parents. The gene mutations found in myelofibrosis are acquired during a person’s lifetime rather than inherited. However, some families do demonstrate a clear predisposition to developing myeloproliferative neoplasms, though this is uncommon.

How often will I need to see my doctor?

The frequency of doctor visits depends on your risk category and symptoms. People with low-risk disease who are being watched without active treatment may need checkups every few months. Those receiving active treatment or with higher-risk disease will likely need more frequent visits. Your healthcare provider will establish a monitoring schedule tailored to your individual situation, which may include regular blood tests and physical examinations.

🎯 Key takeaways

  • Myelofibrosis progresses at different rates for different people—some live for years with manageable symptoms while others experience more rapid progression
  • Your body may try to compensate for scarred bone marrow by producing blood cells in your spleen and liver, causing these organs to enlarge
  • Fatigue from anemia is often the most challenging daily symptom, requiring adjustments to work schedules and household routines
  • Not all patients need immediate treatment—those without symptoms may simply need regular monitoring through “watchful waiting”
  • Four JAK inhibitor medications are now FDA-approved for myelofibrosis, offering options beyond supportive care
  • Family members can provide crucial support by helping with transportation, appointment tracking, and emotional encouragement during clinical trials
  • Eating smaller, more frequent meals may help when an enlarged spleen makes you feel full quickly
  • The disease can transform into acute myeloid leukemia in some cases, which is why close monitoring with your healthcare team is essential